logo
Plus   Neg
Share
Email

MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S.

MorphoSys AG (MOR,MPSYY.PK) and Incyte Corp. (INCY) have agreed on a collaboration and license agreement to further develop and commercialize MorphoSys' anti-CD19 antibody tafasitamab (MOR208) globally. MorphoSys and Incyte will co-commercialize tafasitamab in the U.S. Incyte has exclusive commercialization rights outside of the U.S.

Tafasitamab is an Fc-engineered antibody currently in clinical development for the treatment of B cell malignancies. MorphoSys recently submitted a Biologics License Application for tafasitamab, in combination with lenalidomide, to the FDA for the treatment of relapsed/refractory diffuse large B cell lymphoma.

MorphoSys will receive an upfront payment of $750 million. Incyte will make an equity investment into MorphoSys of $150 million in new American Depositary Shares (ADS) of MorphoSys. Under the terms of the agreement, MorphoSys will be also eligible to receive milestone payments amounting to up to $1.1 billion.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Best Buy Co. Inc. (BBY) Thursday reported a fourth-quarter profit that increased 1.4 percent from last year, while, J. C. Penney Co.'s (JCP) quarterly profit dropped 64 percent. However, the results of the companies topped analysts' estimates. Safavieh LLC recalled about 760 units of Aura and Silas 3-Drawer Chests for possible serious tip-over and entrapment hazards that can result in death or injuries to children, the U.S. Consumer Product Safety Commission said in a statement. The company said the chests are unstable if they are not anchored to the wall. Shares of Standard Chartered Plc were losing around 4 percent in London trading after the bank warned on fiscal 2020 income growth mainly due to coronavirus impact. This was despite reporting a profit before tax in its fourth quarter, compared to last year's loss. For 2020, the company now expects income growth to be below its medium-term target range of 5 percent to 7 percent.
Follow RTT
>